16TH INTERNATIONAL HLA AND IMMUNQGENETICS WORKSHOP TREATMENT OF CHRONIC REJECTION PROJECT

摘要

The important role of preformed HLA antibodies in the outcome of organ transplants has been well demonstrated for the past 40 years. During this same period, the significance of HLA antibody formation after transplantation was largely ignored. It was only in the past 10 years, through the work of the 13th, 14th, and 15th International HLA and Immunogenetics Workshops (IHIWS), that it has become increasingly clear that HLA antibodies formed posttransplantation is the major cause of allograft failure. Despite this new understanding, there were no clear interventional techniques that could reproducibly remove antibody. Therefore, we were left with a cause but no way to improve allograft survival. This was the case until 2008, when an important new development, bortezomib, started being used in transplantation and was shown to remove HLA antibodies.